Novartis is preparing to present the trial findings to regulatory bodies in 2025. Credit: Novartis AG. Novartis has reported positive topline outcomes from the Phase III STEER trial of an ...

Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.

China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

The open-label multicentre trial is set to involve 54 paediatric patients treated with JR-142, compared with the company’s currently marketed growth hormone therapy Growject. Credit: Shutterstock / ...

Figure 1: Artificial intelligence clinical trials, 2020–2025. Source: GlobalData, Pharma Intelligence Center (Accessed: December 2024). © GlobalData. *To date F ...

The company considers the T cell activator to have potential as a treatment option for high tumour mutation burden (TMB-H) cancers or virally associated malignancies. Credit: Meletios Verras / ...

Modified Rodnan Skin Score is the primary endpoint of the TibuSURE trial. Credit: Cesare Andrea Ferrari/Shutterstock. Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the ...

Jemperli is central to GSK’s immuno-oncology research and development efforts. Credit: GSK. GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) ...

Described as an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyktu saw sales of $170m in 2023 according to GlobalData. Credit: Shutterstock / Pormezz Bristol Myers Squibb (BMS) ...